Hold Alembic Pharmaceuticals: Shahina Mukadam

Shahina Mukadam of Fairwealth Securities told CNBC-TV18, "I hold Alembic Pharmaceuticals personally and for a long-term I have been holding it. It is a good long-term investment story. The company is expected to continue to do well because they have good revenues that are likely to come in from the US market."

She further added, "They have tie-up with Ranbaxy Laboratories for new product that they have recently launched and this will drive the growth and it has already starting to reflect in their numbers so I would continue to hold the stock. Valuations are attractive compared to the rest of the pharmaceuticals; of course it is a smallcap."